BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SENDSubmit
What changes can we expect for the SEND world in 2025?
Marc Ellison
Read the latest from our Sensible SEND blog.
Sensible SEND Blog
BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SENDSubmit
Sensible SEND – Supporting Smart People with Smart Science
Marc Ellison
Read the latest blog from Marc Ellison, Director, SEND Solutions, Instem.
AdvanceBiotechCentrusCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SEND
Can good SEND help avoid running a carci study?
Marc Ellison
The ICH S1B guidance is making significant ripples across our industry, potentially saving years of effort in the development of a new drug, and SEND can play its part in enabling this.
Regulatory SubmissionSENDSensible SEND
Virtual Control Groups: Divisive Innovation With SEND
Marc Ellison
The proliferation of standardized nonclinical data has paved the way for us to explore new ways to reuse and repurpose existing study data.
Regulatory SubmissionSENDSensible SEND
Will AI steal my SEND job?
Marc Ellison
AI has clear uses in fraud detection, cybersecurity, and supply chain management, and seems to be used in innovative applications across various industries but does it have an application for SEND?
BiotechCROPharmaceuticalPre-ClinicalRegulatory ComplianceRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SEND
We need to talk about SEND v4.0
Marc Ellison
Due to be published in 2026, SEND 4.0 is the next update due for the SEND standard.
Stay up to Date
Get expert tips, industry news, and fresh content delivered to your inbox.
